Latest News for: pd-l1

Edit

PD-1 Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at ...

GetNews 15 Apr 2025
Due to its numerous indication approvals, which led to a comprehensive FDA label and widespread use across a number of indications, PD-1 exceeds the sales of PD-L1 in the 7MM market.
Edit

Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a ...

GetNews 15 Apr 2025
In biomarker specific specific cases, most number of cases is from PD-L1 followed by KRAS, EGFR ... TECENTRIQ is a PD-L1-blocking antibody ... Cell Lung Cancer without actionable genomic alterations, PD-L1.
Edit

Cancer Immunotherapy Market Size | USD 294.4 Bn & CAGR 8.40% Growth By 2035

Pharmiweb 10 Apr 2025
Market Dynamics ... Inc F ... One of the most prominent trends is the rising use of immune checkpoint inhibitors such as PD-1/PD-L1 and CTLA-4 inhibitors, which have shown remarkable results in treating melanoma, lung, and bladder cancers ... The U.S ... .
Edit

Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ...

GetNews 08 Apr 2025
It further highlights the inactive pipeline products in this space ... AZD4547 ... Upon oral administration, TIGIT/PD-L1 inhibitor AUR-106 simultaneously targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream signaling pathways.
Edit

Head and Neck Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of ...

GetNews 03 Apr 2025
Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status ... Dostarlimab functions by inhibiting the interaction between PD-1 receptors on T-cells and their ligands (PD-L1) on tumor cells.
Edit

Digitise pathology to unlock the potential of precision medicine 

Pharmiweb 01 Apr 2025
Companion diagnostics support the shift toward precision medicine by using biomarker analysis to match patients to the most effective treatments.  Recent advances in computational pathology have ...
Edit

Immunotherapy helps bring more tomorrows for cancer patients in Việt Nam: conference

Vietnam News 31 Mar 2025
He highlighted PD-L1—a protein with a broader presence, including on tumor cells as key to identifying patients for immunotherapy. Based on clinical data and experience, he explained how PD-L1 guides ...
Edit

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Pharmiweb 31 Mar 2025
IMFINZI® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading tactics ...
Edit

Hormone Replacement Therapy Market Poised for Strong Growth, Projected to Expand at a 6.48% CAGR ...

GetNews 31 Mar 2025
... favorable benefit-risk profile of PD-1 inhibitors, including TEVIMBRA® (tislelizumab-jsgr), for the first-line treatment of locally advanced or metastatic ESCC and G/GEJ cancers with PD-L1 >1%.
Edit

Cancer Monoclonal Antibodies Market Poised for Strong Growth, Projected to Expand at a 10% CAGR ...

GetNews 31 Mar 2025
• In March 2025, BeiGene announced FDA approval of TEVIMBRA® (tislelizumab-jsgr) with platinum-based chemotherapy for first-line treatment of PD-L1 (≥1) positive unresectable or metastatic esophageal squamous cell carcinoma (ESCC) ... 1 ... 2 ... 3.
Edit

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

Pharmiweb 28 Mar 2025
Exploratory objectives included immunogenicity and assessment of tumor biomarkers (TMB, PD-L1) ... “hot” ones, and induced T-cell infiltration, as well as PD(L)-1 expression in the tumor microenvironment.
  • 1
×